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ABSTRACT
Background: In Huntington's disease, 60% of the variance in onset age is not explained by the huntingtin gene mutation. Huntington's disease onset was earlier in caffeine users. Objective: The objective of this study was to assess the relationship of lifestyle factors with motor phenoconversion among persons at risk for Huntington's disease. Methods: The associations of motor phenoconversion and exposure to selected lifestyle and health factors were examined using Cox proportional hazards analyses adjusted for age, gender, and repeat length. Results: Of 247 participants, 36 (14.6%) phenoconverted. Mean follow-up was 4.2 years. Greater caffeinated soda use was associated with an increased hazard of phenoconversion: moderate use hazard ratio 2.26 (95% confidence interval 0. 59-8.71 ), high use hazard ratio 4.05 (95% confidence interval 1.18-13.96 Huntington's disease is a fatal, progressive neurodegenerative disorder resulting from a trinucleotide cytosine-adenine-guanine (CAG) expansion in the huntingtin gene. Persons with 37 repeats invariably develop clinical features of Huntington's disease (phenoconversion) during the course of a normal life span, but 30% to 60% of the variability in age of onset remains unexplained. 1 In other chronic neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease, environmental factors can influence risk, and the interaction of genes and the environment is important. Recent reports suggest that environmental factors may modulate neurodegeneration in Huntington's disease. 2 We previously reported analyses of dietary behaviors and phenoconversion in adults at risk for Huntington's disease in the Prospective Huntington At-Risk Observational Study (PHAROS). [3] [4] [5] We now report the relationship of selected lifestyle and health-related behaviors to the onset of Huntington's disease (motor phenoconversion).
Methods

Study Population
Adults at 50% risk for Huntington's disease who wished to remain unaware of their Huntington's disease genotype but consented to provide a coded DNA sample for CAG analysis were enrolled in PHAROS between 1999 and 2004 and followed prospectively until 2010. 5 Motor phenoconversion was determined by a rater, unaware of genotype, based on the motor component of the Unified Huntington's Disease Rating Scale (UHDRS).
Assessment of Clinical Factors
The UHDRS was administered at baseline and follow-up visits. An investigator's response to UHDRS question 17 that a participant's motor abnormalities "are unequivocal signs of Huntington's disease with 99% confidence" for the first time was defined as motor phenoconversion. Depression was assessed using the Beck Depression Inventory administered within 614 days of the environmental survey. Depression was defined as a Beck Depression Inventory >10.
Assessment of Environmental Risk Factors
Information regarding lifelong use of tobacco products, caffeine, alcohol, certain medications (nonsteroidal anti-inflammatory drugs, corticosteroids and, in women, estrogen preparations) and head injury was collected using validated, closed-response questionnaires completed by the participants. 6, 7 Some participants completed the questionnaires at the study baseline and others completed them at a later visit.
Definitions of Exposure Variables
Exposure variables were defined categorically and cumulatively, for the time period prior to phenoconversion, as follows:
1. Tobacco, ever exposed: participants who smoked 100 cigarettes, 50 cigars, 50 pipes, or used 10 pouches of chewing tobacco or cans of snuff; cumulative exposure was calculated in pack-years, defined as one pack of cigarettes/day for 1 year. 2. Alcohol, ever exposed: participants who consumed alcohol at least once a month for at least 6 months; cumulative exposure was calculated as grams of alcohol/day times years of use using standard values of alcohol content for each beverage type (http://www.mayoclinic.com/health/ alcohol/SC00024), with a standard drink equal to 13.7 grams of pure alcohol. 3. Caffeine, ever exposed: participants who consumed 8 oz. of caffeinated coffee, tea, or soda at least once per month for at least 6 months. For each beverage type, cumulative use was calculated in mg of caffeine/day times years of caffeine use using standard values for caffeine content (http://www.mayoclinic.com/health/caffeine/AN01211). 4. Medications, ever exposed: participants who regularly used nonsteroidal anti-inflammatory drugs,
corticosteroids, or, in women, estrogen preparations daily for 2 weeks. 5. Head injury: participants who ever had a head injury resulting in loss of consciousness or amnesia for >5 minutes.
Statistical Methods
Participants with expanded repeats (CAG 37) who had not phenoconverted before or at baseline were included in these analyses. The baseline was the date of survey completion. Cox models to predict time to phenoconversion were run for environmental variables by usage, adjusting for age, gender, and CAG repeat length (continuous).
Results
Description of Participants
A total of 247 PHAROS participants with CAG 37 who completed at least 1 environmental survey were included. Mean follow-up time after survey completion was 4.2 (standard deviation 1.8) years. Of the participants, 74% were women. Median baseline values for demographic and clinical measures were age, 44; years of education, 16; UHDRS motor score, 3; UHDRS chorea score, 0; symbol digit test score, 54; and Beck Depression Score, 3.
Phenoconversion in CAG Expanded Group
Of the 247 participants in the CAG expanded group, 36 (14.6%) phenoconverted following completion of the environmental survey. Analyses of caffeinated soda showed that a history of soda consumption (P 5 .05), higher current soda exposure (P 5 .0376), and higher cumulative soda exposure (P 5 .06) were all significantly associated with phenoconversion, but the use of other caffeinated beverages was not associated with phenoconversion (Table 1) . Regular use of tobacco or alcohol (Table 2) , nonsteroidal antiinflammatory drugs, corticosteroids or, in women, Values shown are number (n, %) or medians (25th and 75th percentiles) and hazard ratios (95% confidence intervals). Probability (P) values are from 2 degrees of freedom tests in separate models to predict phenoconversion, adjusted for age at time of environmental survey, gender, and cytosine-adenine-guanine repeat length (continuous). The reference category is never or none. CI, confidence interval.
estrogens (data not shown) were not associated with phenoconversion.
Discussion
Lifestyle behaviors such as caffeine consumption, cigarette smoking, and alcohol use were not associated with motor phenoconversion, with 1 exception. Drinking caffeinated soda, but not other caffeinated beverages, was associated with phenoconversion. Although this association may be spurious in the setting of multiple comparisons, it is interesting to note that Simonin and colleagues, 8 in a retrospective assessment of persons with established Huntington's disease, also reported that caffeine intake was associated with an earlier age at onset. Although caffeine has been associated with lower risk of developing Parkinson's disease in epidemiologic studies, 9,10 in Parkinson's disease patients taking creatine in a clinical trial, caffeine intake was associated with more rapid disease progression, possibly as a result of a complex interaction with the glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) genotype. 11, 12 Chronic caffeine intake may reduce adenosine A2A receptor activity. 13 In the 3-NP model of Huntington's disease, the A2A receptor antagonism has been associated with a worsening of signs.
14 However, no other forms of caffeine were associated with Huntington's disease risk, nor was a combined caffeine dose associated.
Carbonated soda intake may have adverse health effects independent of caffeine. Sugar containing soda use can increase caloric intake. We previously found increased caloric intake to be associated with higher CAG repeat length and a 5-year probability of Huntington's disease onset. 5 The use of carbonated soda is also associated with a greater risk of metabolic Values shown are number (n, %) or medians (25th and 75th percentiles) and hazard ratios (95% confidence intervals). Probability (P) values are from 2 degrees of freedom tests in separate models to predict phenoconversion, adjusted for age at time of environmental survey, gender, and cytosine-adenine-guanine repeat length (continuous). The reference category is never or none. CI, confidence interval. Vol. 33, No. 3, 2018 syndrome and diabetes, conditions associated with increased systemic inflammatory processes that may in turn be associated with neurodegeneration. 15, 16 In rats, carbonated soft drink intake causes oxidative stress and alters mRNA expression in dopaminergic and serotonergic pathways. 17 In a community-based investigation of stroke risk factors, diet soda intake was associated with increased risk of vascular events, including stroke. 18 Finally, drinking carbonated beverages may result in increased intake of aluminum. 19 Any of these effects, or some combination of these, may plausibly have an adverse effect on the ongoing neurodegenerative processes of Huntington's disease. Replication and laboratory investigation are needed.
No other lifestyle factors assessed in this report were associated with phenoconversion in the PHAROS population, although we previously reported dietary dairy intake and higher caloric intake to be associated with motor phenoconversion. 4, 5 In the Cooperative Huntington's Observational Research Trial Huntington Disease (COHORT HD) study, ever smoking cigarettes was associated with greater risk of phenoconversion in 59 persons with intermediate length (36-39 CAGs) repeats, 20 but we found no increased risk associated with smoking in our analysis of those with 37 repeats. More years of education predicted an earlier age at Huntington's disease onset in a retrospective registry-based analysis. 21 However, in our analyses, the adjustment for education did not significantly influence the results.
This study has limitations. We collected information on lifelong behavior at a single point in time, without corroboration of participants' reports. Information may have been forgotten or incorrectly reported. We found few differences in reported exposures when participants with expanded repeats were compared with those without expanded repeats, however, suggesting that reporting was not biased as a result of "at risk" status. In addition, we collected information on many different factors and have not made corrections for multiple comparisons. We have chosen to report these for future investigation, recognizing that some of the associations we observed may have been by chance. 22 The strengths of this study include the large sample size, prospective follow-up, and collecting data from asymptomatic at-risk persons. Prior reports all used primarily retrospective data collection in persons with established Huntington's disease. In PHAROS, participants were unaware of genotype, an additional strength, suggesting that an awareness of risk status was not likely to have caused a behavioral change or a difference in reporting. However, we have not assessed other exposures, such as toxicant chemicals, that may be proposed to modulate Huntington's disease gene expression. Genetic modifiers of Huntington's disease age at onset have been identified in gene association studies, but large populations were required. 23 Future investigations with larger population sizes investigating the individual and combined effects of genes and environment on Huntington's disease phenoconversion may provide additional insights.
In summary, in PHAROS, motor phenoconversion was generally not affected by the lifestyle factors that we investigated, although in this and our prior analyses, certain dietary patterns, namely, caffeinated soda use, dairy intake, and greater caloric intake were all associated with phenoconversion. Because dietary patterns may be modified, further investigation of these is indicated, and if verified, could lead to recommendations to delay motor phenoconversion. The considerable amount of the non-CAG variance accounting for age at onset remains unexplained.
